Piotr Ponikowski1, Dirk J van Veldhuisen2, Josep Comin-Colet3, Georg Ertl4, Michel Komajda5, Viacheslav Mareev6, Theresa A McDonagh7, Alexander Parkhomenko8, Luigi Tavazzi9, Victoria Levesque10, Claudio Mori10, Bernard Roubert10, Gerasimos Filippatos11, Frank Ruschitzka12, Stefan D Anker13. 1. Department of Cardiology, Military Hospital, Wrocław, Poland. 2. Department of Cardiology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands. 3. Hospital del Mar (IMAS) & Universitat Autonoma de Barcelona Barcelona, Barcelona, Spain. 4. Department of Cardiology, University Würzburg, Würzburg, Germany. 5. Department of Cardiology, University Pierre et Marie Curie, Paris VI and Pitie Salpetriere Hospital, AP-HP, Paris, France. 6. A. L. Myasnikov Cardiology Institute, Moscow, Russia. 7. King's College Hospital, London, UK. 8. Center 'M.D. Strazhesko Institute of Cardiology', National Medical Academy of Science, Kiev, Ukraine. 9. Maria Cecilia Hospital, GVM Care & Research-E.S. Health Science Foundation, Cotignola, Italy. 10. Vifor Pharma Ltd, Glattbrugg, Switzerland. 11. Department of Cardiology, University Athens, Athens, Greece. 12. University Hospital Zurich, Zurich, Switzerland. 13. Department of Innovative Clinical Trials, University Medical Centre Göttingen, Göttingen, Germany.
Abstract
BACKGROUND: Iron deficiency (ID) is a common co-morbidity associated with chronic heart failure (CHF), which has unfavourable clinical and prognostic consequences. In Ferinject Assessment in Patients with IRon Deficiency and Chronic Heart Failure (FAIR-HF), the treatment with i.v. ferric carboxymaltose (FCM) improved symptoms and quality of life over a 24 week period. Ferric CarboxymaltOse evaluatioN on perFormance in patients with IRon deficiency in coMbination with chronic Heart Failure (CONFIRM-HF) was designed to test a simplifieddosage scheme of FCM during a longer follow-up period. METHODS: CONFIRM-HF, a double-blind, multi-centre, prospective, randomized, two-arm study, enrolled ambulatory patients with symptomatic CHF [New York Heart Association (NYHA) class II/III] with left ventricular ejection fraction ≤45%, BNP >100 pg/mL, or NT-proBNP >400 pg/mL, presence of ID [defined as ferritin <100 ng/mL, or ferritin 100-300 ng/mL if transferrin saturation (TSAT) <20%], and haemoglobin (Hb) <15 g/dL. Patients were randomized 1:1 to treatment with FCM or placebo for 52 weeks. Primary endpoint is change in 6-minute walk test (6MWT) distance from baseline to Week 24. Secondary endpoints are: change in 6MWT from baseline to Weeks 6, 12, 36, and 52; Patient Global Assessment score at Weeks 6, 12, 24, 36, and 52; and change from baseline to Weeks 6, 12, 24, 36, and 52 in NYHA class, fatigue score, and quality of life. Safety endpoints include overall safety over the treatment period of 52 weeks. Study medication was administered in single doses as undiluted bolus injection of up to 1000 mg of iron or normal saline at Day 0 and Week 6 up to iron repletion. Further doses of study medication could be administered at Weeks 12, 24, and 36 if a patient still had ID. RESULTS: Overall, 304 patients were recruited in 41 centres in nine countries. CONCLUSION: This study will provide further information on the efficacy and safety of iron therapy with i.v. FCM in CHF patients with ID over a 1 year period using a simplified dosing scheme.
RCT Entities:
BACKGROUND:Iron deficiency (ID) is a common co-morbidity associated with chronic heart failure (CHF), which has unfavourable clinical and prognostic consequences. In Ferinject Assessment in Patients with IRonDeficiency and Chronic Heart Failure (FAIR-HF), the treatment with i.v. ferric carboxymaltose (FCM) improved symptoms and quality of life over a 24 week period. Ferric CarboxymaltOse evaluatioN on perFormance in patients with IRon deficiency in coMbination with chronic Heart Failure (CONFIRM-HF) was designed to test a simplifieddosage scheme of FCM during a longer follow-up period. METHODS: CONFIRM-HF, a double-blind, multi-centre, prospective, randomized, two-arm study, enrolled ambulatory patients with symptomatic CHF [New York Heart Association (NYHA) class II/III] with left ventricular ejection fraction ≤45%, BNP >100 pg/mL, or NT-proBNP >400 pg/mL, presence of ID [defined as ferritin <100 ng/mL, or ferritin 100-300 ng/mL if transferrin saturation (TSAT) <20%], and haemoglobin (Hb) <15 g/dL. Patients were randomized 1:1 to treatment with FCM or placebo for 52 weeks. Primary endpoint is change in 6-minute walk test (6MWT) distance from baseline to Week 24. Secondary endpoints are: change in 6MWT from baseline to Weeks 6, 12, 36, and 52; Patient Global Assessment score at Weeks 6, 12, 24, 36, and 52; and change from baseline to Weeks 6, 12, 24, 36, and 52 in NYHA class, fatigue score, and quality of life. Safety endpoints include overall safety over the treatment period of 52 weeks. Study medication was administered in single doses as undiluted bolus injection of up to 1000 mg of iron or normal saline at Day 0 and Week 6 up to iron repletion. Further doses of study medication could be administered at Weeks 12, 24, and 36 if a patient still had ID. RESULTS: Overall, 304 patients were recruited in 41 centres in nine countries. CONCLUSION: This study will provide further information on the efficacy and safety of iron therapy with i.v. FCM in CHFpatients with ID over a 1 year period using a simplified dosing scheme.
Authors: Maria Domenica Cappellini; Josep Comin-Colet; Angel de Francisco; Axel Dignass; Wolfram Doehner; Carolyn S Lam; Iain C Macdougall; Gerhard Rogler; Clara Camaschella; Rezan Kadir; Nicholas J Kassebaum; Donat R Spahn; Ali T Taher; Khaled M Musallam Journal: Am J Hematol Date: 2017-07-07 Impact factor: 10.047
Authors: Stephan von Haehling; Uwe Gremmler; Michael Krumm; Frank Mibach; Norbert Schön; Jens Taggeselle; Johannes B Dahm; Christiane E Angermann Journal: Clin Res Cardiol Date: 2017-02-22 Impact factor: 5.460
Authors: Piotr Ponikowski; Dirk J van Veldhuisen; Josep Comin-Colet; Georg Ertl; Michel Komajda; Viacheslav Mareev; Theresa McDonagh; Alexander Parkhomenko; Luigi Tavazzi; Victoria Levesque; Claudio Mori; Bernard Roubert; Gerasimos Filippatos; Frank Ruschitzka; Stefan D Anker Journal: Eur Heart J Date: 2014-08-31 Impact factor: 29.983
Authors: Tee Joo Yeo; Poh Shuan Daniel Yeo; Farid Abdul Hadi; Timothy Cushway; Kim Yee Lee; Fang Fang Yin; Anne Ching; Ruili Li; Seet Yoong Loh; Shir Lynn Lim; Raymond Ching-Chiew Wong; Bee Choo Tai; Arthur Mark Richards; Carolyn S P Lam Journal: ESC Heart Fail Date: 2018-01-18